Free Trial

Karyopharm Therapeutics (KPTI) Competitors

Karyopharm Therapeutics logo
$4.65 +0.42 (+9.93%)
Closing price 04:00 PM Eastern
Extended Trading
$4.62 -0.03 (-0.54%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KPTI vs. BIOA, IKT, BDTX, ALEC, TIL, GALT, LXEO, KYTX, RAPT, and LYEL

Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include BioAge Labs (BIOA), Inhibikase Therapeutics (IKT), Black Diamond Therapeutics (BDTX), Alector (ALEC), Instil Bio (TIL), Galectin Therapeutics (GALT), Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.

Karyopharm Therapeutics vs. Its Competitors

BioAge Labs (NASDAQ:BIOA) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Karyopharm Therapeutics has a consensus price target of $43.20, suggesting a potential upside of 829.03%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than BioAge Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAge Labs
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Karyopharm Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 1 mentions for BioAge Labs. Karyopharm Therapeutics' average media sentiment score of 0.00 beat BioAge Labs' score of -0.17 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Karyopharm Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioAge Labs has higher earnings, but lower revenue than Karyopharm Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAge LabsN/AN/A-$71.11MN/AN/A
Karyopharm Therapeutics$145.24M0.28-$76.42M-$13.26-0.35

BioAge Labs has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -43.99%.

Company Net Margins Return on Equity Return on Assets
BioAge LabsN/A N/A N/A
Karyopharm Therapeutics -43.99%N/A -35.95%

Summary

Karyopharm Therapeutics beats BioAge Labs on 7 of the 11 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KPTI vs. The Competition

MetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$36.55M$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.06%
P/E Ratio-0.358.9827.0020.10
Price / Sales0.28729.50435.75120.29
Price / CashN/A159.8036.8257.86
Price / Book-0.214.517.985.56
Net Income-$76.42M$31.26M$3.16B$248.40M
7 Day Performance6.65%5.57%3.69%6.04%
1 Month Performance3.56%5.48%2.91%7.69%
1 Year Performance-60.76%1.14%34.30%20.97%

Karyopharm Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPTI
Karyopharm Therapeutics
3.8128 of 5 stars
$4.65
+9.9%
$43.20
+829.0%
-65.6%$36.55M$145.24M-0.35380High Trading Volume
BIOA
BioAge Labs
N/A$4.13
-1.7%
N/AN/A$148.06MN/A0.00N/A
IKT
Inhibikase Therapeutics
1.3389 of 5 stars
$1.95
+20.4%
$6.50
+233.3%
+66.4%$144.97M$260K-0.736
BDTX
Black Diamond Therapeutics
2.9707 of 5 stars
$2.48
+5.5%
$14.60
+488.7%
-44.1%$141.01MN/A41.3390Positive News
ALEC
Alector
3.816 of 5 stars
$1.40
-5.4%
$4.00
+185.7%
-67.2%$139.99M$100.56M-1.11270
TIL
Instil Bio
3.1367 of 5 stars
$20.83
-9.3%
$119.00
+471.3%
+139.0%$136.62MN/A-1.74410
GALT
Galectin Therapeutics
1.639 of 5 stars
$2.11
-9.4%
$6.00
+184.4%
+4.4%$133.54MN/A-2.939Gap Up
LXEO
Lexeo Therapeutics
2.4217 of 5 stars
$4.02
-2.4%
$16.60
+312.9%
-70.7%$133.46M$650K-1.2258News Coverage
KYTX
Kyverna Therapeutics
1.2748 of 5 stars
$3.07
-6.4%
$18.50
+502.6%
-63.6%$132.69M$7.03M-0.9196Gap Down
RAPT
Rapt Therapeutics
4.1263 of 5 stars
$8.00
-5.1%
$24.00
+200.0%
-63.6%$132.32M$1.53M-0.4280
LYEL
Lyell Immunopharma
2.5676 of 5 stars
$8.84
-1.1%
$15.00
+69.7%
-68.4%$130.92M$60K-0.35270

Related Companies and Tools


This page (NASDAQ:KPTI) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners